1. Home
  2. WST vs BIIB Comparison

WST vs BIIB Comparison

Compare WST & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • WST
  • BIIB
  • Stock Information
  • Founded
  • WST 1923
  • BIIB 1978
  • Country
  • WST United States
  • BIIB United States
  • Employees
  • WST N/A
  • BIIB N/A
  • Industry
  • WST Medical/Dental Instruments
  • BIIB Biotechnology: Pharmaceutical Preparations
  • Sector
  • WST Health Care
  • BIIB Health Care
  • Exchange
  • WST Nasdaq
  • BIIB Nasdaq
  • Market Cap
  • WST 20.1B
  • BIIB 24.2B
  • IPO Year
  • WST N/A
  • BIIB 1991
  • Fundamental
  • Price
  • WST $262.43
  • BIIB $168.52
  • Analyst Decision
  • WST Strong Buy
  • BIIB Buy
  • Analyst Count
  • WST 9
  • BIIB 24
  • Target Price
  • WST $354.50
  • BIIB $174.62
  • AVG Volume (30 Days)
  • WST 795.3K
  • BIIB 1.8M
  • Earning Date
  • WST 10-23-2025
  • BIIB 10-30-2025
  • Dividend Yield
  • WST 0.34%
  • BIIB N/A
  • EPS Growth
  • WST 0.17
  • BIIB N/A
  • EPS
  • WST 6.75
  • BIIB 10.97
  • Revenue
  • WST $3,017,900,000.00
  • BIIB $10,065,900,000.00
  • Revenue This Year
  • WST $6.97
  • BIIB $2.97
  • Revenue Next Year
  • WST $6.11
  • BIIB N/A
  • P/E Ratio
  • WST $38.71
  • BIIB $15.27
  • Revenue Growth
  • WST 4.92
  • BIIB 4.77
  • 52 Week Low
  • WST $187.43
  • BIIB $110.04
  • 52 Week High
  • WST $348.90
  • BIIB $175.86
  • Technical
  • Relative Strength Index (RSI)
  • WST 40.53
  • BIIB 74.64
  • Support Level
  • WST $262.48
  • BIIB $151.83
  • Resistance Level
  • WST $280.11
  • BIIB $157.79
  • Average True Range (ATR)
  • WST 9.13
  • BIIB 5.59
  • MACD
  • WST -2.99
  • BIIB 1.37
  • Stochastic Oscillator
  • WST 9.48
  • BIIB 95.37

About WST West Pharmaceutical Services Inc.

West Pharmaceutical Services is based in Pennsylvania and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), nonglass containment solutions, and auto-injectors for injectable drugs, which include large-molecule biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.

About BIIB Biogen Inc.

Biogen is an established biopharmaceutical company focused on treatments for neurological diseases and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 45% of total revenue in 2024. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (18% of total in 2024), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).

Share on Social Networks: